Entry Rationale
The current price is positioned above the support level based on the REPORTING output, suggesting the maintenance of an upward trend and additional potential for increase, warranting consideration for entry.
ICU Medical raises 2026 adjusted EPS outlook to $8.60-$9.00 amid 41.5% gross margin view
ICU Medical's announcement of an upward revision to its 2026 adjusted EPS forecast is a key catalyst that raises expectations for performance improvement.
The current price is positioned above the support level based on the REPORTING output, suggesting the maintenance of an upward trend and additional potential for increase, warranting consideration for entry.
If the current upward trend continues and reaches the resistance level of $176.27, I will take profits, and if it falls below the support level of $151.16, I will cut losses.
RSI(14) 55.6, moving averages in a positive arrangement, trading volume 1.11 times the 20-day average, and a recent 7-day volatility of +3.1% indicate a favorable trend.
The actual return recorded was 10.9%, surpassing the expected return of 2.8%, resulting in an OVERHIT designation. A strong positive factor was the upward revision of the 2026 adjusted EPS forecast, along with the alignment of moving averages at the time of entry and a trading volume of 1.11 times the 20-day average, which supported the upward momentum. However, the actual market reaction was much stronger than the anticipated target, indicating that the upward pressure when combining the strength of the positive factors and the rising theme trend was not fully reflected.
In future trading, if there is a simultaneous capture of clear fundamental improvement news, such as earnings upgrades, and an increasing trend of news within the theme, we will apply a strategy that allows for a slightly more flexible target price. However, the established support levels and stop-loss criteria will be strictly adhered to, prioritizing risk management above all.